Katherine Antel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine Antel has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Jenna Oosthuizen
Department of Medicine, Division of Clinical Haematology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
8 shared publications- Estelle Verburgh
Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
7 shared publications Estelle Verburgh
University of Cape Town Cape Town South Africa
6 shared publicationsFrancois Malherbe
Division of General Surgery, Department of Surgery, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital
6 shared publicationsGary Maartens
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
6 shared publications- Dharshnee Rama Chetty
University of Cape Town
4 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70394
Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting
In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach capturing molecular features of lymphoma and key pathogens. Plasma cfDNA undergoes ultra‐low‐pass whole genome sequencing and deep targeted sequencing (50,000× coverage). The combined output—including estimated tumor fraction, mutations, copy number alterations, structural variants, B‐ and T‐cell receptor clonality, and pathogen detection—is integrated into a machine‐learning classifier developed within this study to differentiate malignant from benign lymphadenopathy. In a prospective cohort of 124 South African patients with lymphadenopathy due to lymphoma (76.6%), benign causes (18.6%; TB adenitis [9.7%] and reactive [8.9%]), and disseminated solid tumors (4.8%), patients with lymphoma had higher cfDNA concentrations (mean 248.3 ng/mL), tumor fraction (mean 11.6%), and more mutations (mean 9.5), frequently in KMT2C , SOCS1 , TP53 , STAT3 , and CREBBP . Targeted structural variants were 100% specific for lymphoma. The ADLiB machine‐learning classifier distinguished malignant from benign lymphadenopathy within this cohort with 95% sensitivity, 75% specificity, and 92% accuracy (AUC 0.89). ADLiB provides a minimally invasive and feasible diagnostic approach to distinguish malignant from benign lymphadenopathy in resource‐limited settings with high pathogen prevalence that can complicate lymphoma diagnosis. With further optimization and clinical validation, this cfDNA‐based approach has the potential to accelerate and improve lymphoma diagnosis where traditional diagnostics are constrained.
- 29 May 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70394
Open AccessAccess to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting
In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach capturing molecular features of lymphoma and key pathogens. Plasma cfDNA undergoes ultra‐low‐pass whole genome sequencing and deep targeted sequencing (50,000× coverage). The combined output—including estimated tumor fraction, mutations, copy number alterations, structural variants, B‐ and T‐cell receptor clonality, and pathogen detection—is integrated into a machine‐learning classifier developed within this study to differentiate malignant from benign lymphadenopathy. In a prospective cohort of 124 South African patients with lymphadenopathy due to lymphoma (76.6%), benign causes (18.6%; TB adenitis [9.7%] and reactive [8.9%]), and disseminated solid tumors (4.8%), patients with lymphoma had higher cfDNA concentrations (mean 248.3 ng/mL), tumor fraction (mean 11.6%), and more mutations (mean 9.5), frequently in KMT2C , SOCS1 , TP53 , STAT3 , and CREBBP . Targeted structural variants were 100% specific for lymphoma. The ADLiB machine‐learning classifier distinguished malignant from benign lymphadenopathy within this cohort with 95% sensitivity, 75% specificity, and 92% accuracy (AUC 0.89). ADLiB provides a minimally invasive and feasible diagnostic approach to distinguish malignant from benign lymphadenopathy in resource‐limited settings with high pathogen prevalence that can complicate lymphoma diagnosis. With further optimization and clinical validation, this cfDNA‐based approach has the potential to accelerate and improve lymphoma diagnosis where traditional diagnostics are constrained.
- Open Access
- 2 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards
Background: Lymphoma real-world observational data and accurate diagnostic systems are lacking in low-resource HIV-endemic settings. We established a new lymphoma registry to generate internationally comparable, clinically validated data, with up-to-date disease classification. We also describe our findings on aggressive B-cell lymphoma. Methods: The descriptive retrospective cohort included patients ≥ 13 years of age newly diagnosed with lymphoma from 2005 to 2020. Patients were enrolled at a single site in a registry with hierarchical groupings to capture, interrogate, and subtype lymphoma diagnoses. These were standardised on the most recent version of the World Health Organisation Classification of Haematolymphoid Tumours (WHO-HAEM5) and correlated with the novel International Consensus Classification of mature lymphoid neoplasms (ICC). Differences due to nomenclature and diagnostic category were annotated. Results: The cohort consisted of 2354 incident lymphoma cases; 1891 (80.3%) non-Hodgkin lymphoma and 463 (19.7%) Hodgkin lymphoma (HL). Twenty-one lymphoma NOS cases were excluded due to inadequate specimen for standardised subclassification. Overall reclassification according to WHO-HAEM5 was 25.8% ( n = 608). Notable nomenclature differences between WHO-HAEM5 and ICC included 44 (1.9%) transformations of indolent B-cell lymphomas; also 857 (36.4%) lymphoid proliferations and lymphomas associated with immune deficiency/dysregulation due to HIV (33.1%) and EBV (31.8%). EBV-association was highest among HL cases, of which 77 (50.3%) were HIV reactive. Conclusion: We report here the impact of adopting international lymphoma classification standards in an HIV-endemic setting. Our findings highlight the persistent prevalence of large B-cell lymphoma, raise concern around inadequate HIV suppression as a potential ongoing driver of disease in our setting, and provide further evidence for EBV-associated HL as a distinct subtype.
- 2 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards
Background: Lymphoma real-world observational data and accurate diagnostic systems are lacking in low-resource HIV-endemic settings. We established a new lymphoma registry to generate internationally comparable, clinically validated data, with up-to-date disease classification. We also describe our findings on aggressive B-cell lymphoma. Methods: The descriptive retrospective cohort included patients ≥ 13 years of age newly diagnosed with lymphoma from 2005 to 2020. Patients were enrolled at a single site in a registry with hierarchical groupings to capture, interrogate, and subtype lymphoma diagnoses. These were standardised on the most recent version of the World Health Organisation Classification of Haematolymphoid Tumours (WHO-HAEM5) and correlated with the novel International Consensus Classification of mature lymphoid neoplasms (ICC). Differences due to nomenclature and diagnostic category were annotated. Results: The cohort consisted of 2354 incident lymphoma cases; 1891 (80.3%) non-Hodgkin lymphoma and 463 (19.7%) Hodgkin lymphoma (HL). Twenty-one lymphoma NOS cases were excluded due to inadequate specimen for standardised subclassification. Overall reclassification according to WHO-HAEM5 was 25.8% ( n = 608). Notable nomenclature differences between WHO-HAEM5 and ICC included 44 (1.9%) transformations of indolent B-cell lymphomas; also 857 (36.4%) lymphoid proliferations and lymphomas associated with immune deficiency/dysregulation due to HIV (33.1%) and EBV (31.8%). EBV-association was highest among HL cases, of which 77 (50.3%) were HIV reactive. Conclusion: We report here the impact of adopting international lymphoma classification standards in an HIV-endemic setting. Our findings highlight the persistent prevalence of large B-cell lymphoma, raise concern around inadequate HIV suppression as a potential ongoing driver of disease in our setting, and provide further evidence for EBV-associated HL as a distinct subtype.
- Open Access
- 25 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1813
Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
Background: Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking. Method: This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography / computed tomography (PET/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed. Results: The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%, P = 0.599) as was 5-year PFS (83% vs. 88%, P = 0.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients ( P = 0.684), and PFS was 100% and 82%, respectively ( P = 0.086). Conclusions: This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.
- 25 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1813
Open AccessEarly-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
Background: Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking. Method: This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography / computed tomography (PET/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed. Results: The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%, P = 0.599) as was 5-year PFS (83% vs. 88%, P = 0.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients ( P = 0.684), and PFS was 100% and 82%, respectively ( P = 0.086). Conclusions: This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.
- Open Access
- 9 June 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 1
Corrigendum: Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
In the original published article, Adams EC, Antel K, Bailey JL, et al. Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region. S Afr J HIV Med. 2025;26(1):a1679. https://doi.org/10.4102/sajhivmed.v26i1.1679, the authors wish to also acknowledge the funder, the Cancer Association of South Africa (CANSA). Instead of: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345. It should be: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345 and the Cancer Association of South Africa (CANSA). The authors apologise for this error. The correction does not change the study’s findings of significance or overall interpretati
- 9 June 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 1
Open AccessCorrigendum: Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
In the original published article, Adams EC, Antel K, Bailey JL, et al. Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region. S Afr J HIV Med. 2025;26(1):a1679. https://doi.org/10.4102/sajhivmed.v26i1.1679, the authors wish to also acknowledge the funder, the Cancer Association of South Africa (CANSA). Instead of: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345. It should be: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345 and the Cancer Association of South Africa (CANSA). The authors apologise for this error. The correction does not change the study’s findings of significance or overall interpretati
- Open Access
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 7
Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
Background: Extrapulmonary tuberculosis (EPTB) is common among people living with HIV (PLWH). Abdominal ultrasound is an accessible investigation, frequently employed to support the diagnosis of EPTB, but may lead to misdiagnoses of diseases with overlapping clinical features, such as lymphoma. Objectives: To describe the abdominal ultrasound features and confirmed diagnoses of patients referred to a biopsy clinic with unexplained lymphadenopathy. Method: This was a retrospective descriptive study of patients attending the peripheral lymph node biopsy clinic at Groote Schuur Hospital between 2017 and 2020, who had abdominal ultrasound examinations while being investigated for unexplained lymphadenopathy. Ultrasound features were compared to the final diagnosis made on the lymph node biopsy. Results: Thirty-four patients were included, most of whom were PLWH (59%). Approximately one-third had a confirmed diagnosis of lymphoma (29%) and approximately one-third had a confirmed diagnosis of tuberculosis (32%). Splenic hypoechoic lesions were more common in patients with lymphoma (64%) than in patients with tuberculosis (46%) and malignancy (17%). Ascites was equally distributed between patients with tuberculosis (36%) and lymphoma (36%). The ultrasound report and confirmed diagnoses agreed in 40% of patients with tuberculosis. Additionally, 36% of patients with confirmed lymphoma were suspected to have tuberculosis based on the abdominal ultrasound. Conclusion: Abdominal ultrasound abnormalities such as splenic hypoechoic lesions, lymphadenopathy, and ascites/pleural effusion have a differential diagnosis including both tuberculosis and lymphoma, and should be investigated accordingly.
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 7
Open AccessDiagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
Background: Extrapulmonary tuberculosis (EPTB) is common among people living with HIV (PLWH). Abdominal ultrasound is an accessible investigation, frequently employed to support the diagnosis of EPTB, but may lead to misdiagnoses of diseases with overlapping clinical features, such as lymphoma. Objectives: To describe the abdominal ultrasound features and confirmed diagnoses of patients referred to a biopsy clinic with unexplained lymphadenopathy. Method: This was a retrospective descriptive study of patients attending the peripheral lymph node biopsy clinic at Groote Schuur Hospital between 2017 and 2020, who had abdominal ultrasound examinations while being investigated for unexplained lymphadenopathy. Ultrasound features were compared to the final diagnosis made on the lymph node biopsy. Results: Thirty-four patients were included, most of whom were PLWH (59%). Approximately one-third had a confirmed diagnosis of lymphoma (29%) and approximately one-third had a confirmed diagnosis of tuberculosis (32%). Splenic hypoechoic lesions were more common in patients with lymphoma (64%) than in patients with tuberculosis (46%) and malignancy (17%). Ascites was equally distributed between patients with tuberculosis (36%) and lymphoma (36%). The ultrasound report and confirmed diagnoses agreed in 40% of patients with tuberculosis. Additionally, 36% of patients with confirmed lymphoma were suspected to have tuberculosis based on the abdominal ultrasound. Conclusion: Abdominal ultrasound abnormalities such as splenic hypoechoic lesions, lymphadenopathy, and ascites/pleural effusion have a differential diagnosis including both tuberculosis and lymphoma, and should be investigated accordingly.
- 6 December 2022
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (4) , 587-594
Focused investigations to expedite cancer diagnosis among patients with lymphadenopathy in a tuberculosis and HIV-endemic region
Purpose: In tuberculosis (TB)-endemic areas, lymphadenopathy is frequently due to TB adenitis, but lymphoma and cancers are important differential diagnoses and critical to diagnose at the earliest opportunity. Key obstacles to lymphoma diagnosis include empiric TB treatment and difficulty accessing a biopsy. We report on a specialized clinic utilizing high-yield investigations for patients with lymphadenopathy. Methods: This prospective interventional study investigated the utility of a core biopsy and the Xpert MTB/RIF Ultra (Ultra) on fine-needle aspirate (FNA) and tissue in a newly established lymph node biopsy clinic over 4 years. Electronic referral facilitated patient assessment within a week. Hematology fellows without specialist surgical or radiological expertise performed the biopsy on the first visit. Results: In 277 patients, including 43% people with HIV, TB was the most frequent diagnosis (34%), followed by lymphoma (27%) and other cancers (17%). Patients were seen a median of 5 days [interquartile range (IQR) 2–8.5 days] from referral. Core biopsy provided sufficient tissue for diagnosis in 96% of patients with lymphoma (72/75) and 94% of patients with cancer (44/47). FNA Ultra had a sensitivity of 73.9% [34/46; 95% confidence interval (CI) 58.9–85.7], and tissue Ultra 73% (46/63; 95% CI 60.3–83.4). There were six false-positive Ultra tests, highlighting the value of histology to either support TB or make an alternative diagnosis. Conclusion: Core biopsies collected under the conditions described are safe and sensitive and can yield a rapid diagnosis. Combining Ultra and a core biopsy can accurately diagnose TB and cancer. This clinic provides an implementation model for resource-constrained and TB-endemic areas.
- 6 December 2022
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (4) , 587-594
Focused investigations to expedite cancer diagnosis among patients with lymphadenopathy in a tuberculosis and HIV-endemic region
Purpose: In tuberculosis (TB)-endemic areas, lymphadenopathy is frequently due to TB adenitis, but lymphoma and cancers are important differential diagnoses and critical to diagnose at the earliest opportunity. Key obstacles to lymphoma diagnosis include empiric TB treatment and difficulty accessing a biopsy. We report on a specialized clinic utilizing high-yield investigations for patients with lymphadenopathy. Methods: This prospective interventional study investigated the utility of a core biopsy and the Xpert MTB/RIF Ultra (Ultra) on fine-needle aspirate (FNA) and tissue in a newly established lymph node biopsy clinic over 4 years. Electronic referral facilitated patient assessment within a week. Hematology fellows without specialist surgical or radiological expertise performed the biopsy on the first visit. Results: In 277 patients, including 43% people with HIV, TB was the most frequent diagnosis (34%), followed by lymphoma (27%) and other cancers (17%). Patients were seen a median of 5 days [interquartile range (IQR) 2–8.5 days] from referral. Core biopsy provided sufficient tissue for diagnosis in 96% of patients with lymphoma (72/75) and 94% of patients with cancer (44/47). FNA Ultra had a sensitivity of 73.9% [34/46; 95% confidence interval (CI) 58.9–85.7], and tissue Ultra 73% (46/63; 95% CI 60.3–83.4). There were six false-positive Ultra tests, highlighting the value of histology to either support TB or make an alternative diagnosis. Conclusion: Core biopsies collected under the conditions described are safe and sensitive and can yield a rapid diagnosis. Combining Ultra and a core biopsy can accurately diagnose TB and cancer. This clinic provides an implementation model for resource-constrained and TB-endemic areas.
- 13 September 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (14) , 3417-3421
Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics
Infectious disease epidemics may overshadow and exacerbate existing challenges in diagnosing lymphoma. We describe pragmatic strategies we have implemented to overcome diagnostic obstacles caused by the local tuberculosis (TB) and HIV epidemics in South Africa, which may serve as a guide to minimize diagnostic delay during the COVID-19 pandemic. We report on the diagnostic utility of a rapid-access lymph node core-biopsy clinic, where lymph node biopsies are taken from outpatients at their first visit. Analysis of tissue biopsies (n = 110) revealed the three most common conditions diagnosed were TB adenitis (34%), lymphoma (29%), and disseminated malignancy (20%). A first-attempt core-biopsy was able to diagnose lymphoma in 27/32 (84%) of cases. Compared with a historical cohort, the diagnostic interval (time from first health visit to diagnostic biopsy) for patients with lymphoma was significantly shorter, 13.5 vs 48 days (p = 0.002).
- 13 September 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (14) , 3417-3421
Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics
Infectious disease epidemics may overshadow and exacerbate existing challenges in diagnosing lymphoma. We describe pragmatic strategies we have implemented to overcome diagnostic obstacles caused by the local tuberculosis (TB) and HIV epidemics in South Africa, which may serve as a guide to minimize diagnostic delay during the COVID-19 pandemic. We report on the diagnostic utility of a rapid-access lymph node core-biopsy clinic, where lymph node biopsies are taken from outpatients at their first visit. Analysis of tissue biopsies (n = 110) revealed the three most common conditions diagnosed were TB adenitis (34%), lymphoma (29%), and disseminated malignancy (20%). A first-attempt core-biopsy was able to diagnose lymphoma in 27/32 (84%) of cases. Compared with a historical cohort, the diagnostic interval (time from first health visit to diagnostic biopsy) for patients with lymphoma was significantly shorter, 13.5 vs 48 days (p = 0.002).